Evidence map›Paper›PMID 28499366›Full record

Observational studyBMC cancer2017

The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.

Danielle Bogan, Lucio Meile, Ahmed El Bastawisy, Hend F Yousef, Abdel-Rahman N Zekri, Abeer A Bahnassy, Wael M ElShamy

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMC cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Targeting alternative splicing in cancer immunotherapy.Frontiers in cell and developmental biology · 2023
    Review
  3. Article
  4. Article
  5. BRCA1-No Matter How You Splice It.Cancer research · 2019
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Danielle BoganCancer Institute, University of Mississippi Medical Center, 2500 N. State Street, Jackson, MS, 39216, USA.
Lucio MeileDepartment of Genetics, Louisiana State University, Louisiana, USA.
Ahmed El BastawisyMedical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt.
Hend F YousefCytogenetics and Molecular Genetics, National Cancer Institute, Cairo University, Cairo, Egypt.
Abdel-Rahman N ZekriVirology and Immunology, National Cancer Institute, Cairo University, Cairo, Egypt.
Abeer A BahnassyMolecular Pathology, National Cancer Institute, Cairo University, Cairo, Egypt.
Wael M ElShamyCancer Institute, University of Mississippi Medical Center, 2500 N. State Street, Jackson, MS, 39216, USA. welshamy@sdbri.org.
Cairo University · EGJackson Memorial Hospital · USLouisiana State University · USSan Diego Biomedical Research Institute · US

Funding

Bi-directional interactions with tumor microenvironment enhance BRCA1-IRIS overexpressing TNBC tumor cells aggressivenessR01CA194447 · NCI · UNIVERSITY OF MISSISSIPPI MED CTR · PI ELSHAMY, WAEL M. · 2015 to 2019
$1.9M
NCI NIH HHS R01 CA194447
6 · The paper itself

Abstract

backgroundBreast cancer is the most globally diagnosed female cancer, with the triple negative breast cancer (TNBC) being the most aggressive subtype of the disease. In this study we aimed at comparing the effect of BRCA1-IRIS overexpression on the clinico-pathological characteristics in breast cancer patients with TNBC or non-TNBC in the largest comprehensive cancer center in Egypt.

methodsTo reach this goal, we conducted an observational study at the National Cancer Institute (NCI), Cairo University (Cairo, Egypt). The data on all diagnosed breast cancer patients, between 2009 and 2012, were reviewed. BRCA1-IRIS expression measured using real time RT/PCR in these patients' tumor samples was correlated to tumor characteristics, such as to clinico-pathological features, therapeutic responses, and survival outcomes.

results96 patients were enrolled and of these 45% were TNBC, and 55% were of other subtypes (hereafter, non-TNBC). All patients presented with invasive ductal carcinomas. No significant difference was observed for risk factors, such as age and menopausal status between the TNBC and the non-TNBC groups except after BRCA1-IRIS expression was factored in. The majority of the tumors in both groups were ≤5 cm at surgery (p = 0.013). However, in the TNBC group, ≤5 cm tumors were BRCA1-IRIS-overexpressing, whereas in the non-TNBC group they were BRCA1-IRIS-negative (p = 0.00007). Most of the TNBC patients diagnosed with grade 1 or 2 were BRCA1-IRIS-overexpressing, whereas non-TNBCs were IRIS-negative (p = 0.00035). No statistical significance was measured in patients diagnosed with grade 3 tumors. Statistically significant difference between TNBCs and non-TNBCs and tumor stage with regard to BRCA1-IRIS-overexpression was observed. Presence of axillary lymph node metastases was positively associated with BRCA1-IRIS overexpression in TNBC group, and with BRCA1-IRIS-negative status in the non-TNBC group (p = 0.00009). Relapse after chemotherapy (p < 0.00001), and local recurrence/distant metastasis after surgery (p = 0.0028) were more pronounced in TNBC patients with BRCA1-IRIS-overexpressing tumors compared to non-TNBC patients. Finally, decreased disease-free survival in TNBC/BRCA1-IRIS-overexpressing patients compared to TNBC/BRCA1-IRIS-negative patients, and decreased overall survival in TNBC as well as non-TNBC patients was driven by BRCA1-IRIS overexpression.

conclusionsTNBC/BRCA1-IRIS-overexpressing tumors are more aggressive than TNBC/BRCA1-IRIS-negative or non-TNBC/BRCA1-IRIS-overexpressing or both negative tumors. Further studies are warranted to define whether BRCA1-IRIS drives the early TNBC lesions growth and dissemination and whether it could be used as a diagnostic biomarker and/or therapeutic target for these lesions at an early stage setting.

Indexed as

AdultAgedAxillaBiomarkers, TumorBRCA1 ProteinCarcinoma, Ductal, BreastDisease-Free SurvivalEgyptErb-b2 Receptor Tyrosine KinasesFemaleHumansLymphatic MetastasisLymph NodesMiddle AgedNeoplasm Recurrence, LocalReceptors, EstrogenBiomarkers, TumorBRCA1 ProteinBRCA1 protein, humanERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneBRCA1-IRISBreast cancerBreast cancer early lesionEgyptMetastasisTriple negativeTumor-initiating cells

Identifiers

PMID28499366
PMCPMC5429567
OpenAlexW2613482175

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.